Clinical Trial Detail

NCT ID NCT02115542
Title Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

bile duct carcinoma

gallbladder carcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.